FILING ANALYSIS · MONDAY, NOVEMBER 2
Seaport Therapeutics, Inc. SPTX — 8-K: Results of Operations and Financial Condition
neutral
Seaport Therapeutics reported positive topline data from a Phase 1 trial of GlyphAllo and dosed the first patient in a Phase 2a trial of GlyphAgo, with cash and investments of $403.8 million expected to fund operations into 2029, but no significant quantified surprises were disclosed
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →